Wall Street Zen upgraded shares of Crescent Biopharma (NASDAQ:CBIO - Free Report) from a sell rating to a hold rating in a research note issued to investors on Sunday.
Other equities research analysts also recently issued research reports about the stock. TD Cowen upgraded shares of Crescent Biopharma to a "strong-buy" rating in a research note on Friday, June 20th. Stifel Nicolaus started coverage on shares of Crescent Biopharma in a research report on Wednesday, June 25th. They set a "buy" rating and a $28.00 price target on the stock. Lifesci Capital upgraded shares of Crescent Biopharma to a "strong-buy" rating and set a $22.00 price target on the stock in a research report on Wednesday, June 18th. Finally, Wedbush started coverage on shares of Crescent Biopharma in a research report on Monday, July 14th. They set an "outperform" rating and a $27.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $25.67.
Get Our Latest Report on Crescent Biopharma
Crescent Biopharma Stock Performance
Shares of NASDAQ:CBIO traded up $0.14 on Friday, hitting $13.18. The stock had a trading volume of 120,706 shares, compared to its average volume of 132,421. Crescent Biopharma has a twelve month low of $11.06 and a twelve month high of $63.00. The company has a market capitalization of $257.67 million, a PE ratio of -0.29 and a beta of 1.52.
About Crescent Biopharma
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Read More
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
